Immunome Inc. License Agreements
6 Contracts & Agreements
- Amendment No. 2 to License Agreement, dated August 7, 2024, by and between Immunome, Inc. and Bristol-Myers Squibb Company (Filed With SEC on November 13, 2024)
- License Agreement, by and between the registrant and Zentalis Pharmaceuticals, Inc., dated January 5, 2024 (Filed With SEC on March 28, 2024)
- License Agreement dated November 29, 2017, by and between Immunome, Inc. (as assignee) and Bristol-Myers Squibb Company, as amended (Filed With SEC on March 26, 2024)
- Master License Agreement, by and between Morphimmune, Inc. and Purdue Research Foundation, dated as of January 19, 2021, as modified pursuant to that certain email by Max Rosett... (Filed With SEC on August 8, 2023)
- Amendment #2 to the License Agreement by and between the registrant and Arrayjet Limited, dated December 30, 2022 (Filed With SEC on March 16, 2023)
- Second Amendment to License Agreement by and between the registrant and Thomas Jefferson University, dated July 28, 2020 (Filed With SEC on November 16, 2020)
